BeiGene, Ltd.
BGNE
株式のランク
#1179
BeiGene, Ltd. is a global biotechnology enterprise that operates across the... BeiGene, Ltd. is a global biotechnology enterprise that operates across the entire pharmaceutical value chain, encompassing the research, development, production, and worldwide commercialization of diverse therapeutic agents. The company's commercially available product lineup includes several important medicines: BRUKINSA, an agent used for relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab, prescribed for R/R classical Hodgkin's lymphoma; REVLIMID, indicated for multiple myeloma; VIDAZA, which addresses myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA, a treatment for giant cell tumor of bone; BLINCYTO, for acute lymphoblastic leukemia; KYPROLIS, another therapy for R/R multiple myeloma; SYLVANT, targeting idiopathic multicentric Castleman disease; QARZIBA, for neuroblastoma; Pamiparib, applicable to various solid tumors; and Pobevcy, indicated for metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). Within its robust clinical development pipeline, BeiGene is actively advancing numerous investigational compounds. Key candidates include Zanubrutinib, a BTK inhibitor designed to combat lymphomas; Tislelizumab, an anti-PD-1 antibody under investigation for a spectrum of solid and hematological cancers; Lifirafenib and BGB-3245, both in trials for melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor targeting NSCLC, melanoma, and other solid tumors. Further expanding its clinical assets are BGB-A333, a PD-L1 inhibitor for diverse solid tumors; Ociperlimab, a TIGIT inhibitor also aimed at various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor for mature B-cell malignancies; BGB-A445, an OX40 agonist antibody for solid tumors; Zanidatamab, a bispecific HER2 inhibitor addressing breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor for a range of solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene has also established strategic alliances with prominent industry partners, including Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. The company, incorporated in 2010, maintains its corporate headquarters in Cambridge, Massachusetts.
株価
$184.00
最終同期: 2025-01-02
時価総額
$19.28B
変化（1日）
-0.38%
変化（1年）
0.00%
国
US
取引 BeiGene, Ltd. (BGNE)
カテゴリー
Healthcare
BeiGene, Ltd.（BGNE）の収益
Jun 2026 時点の収益 TTM: $6.13B
BeiGene, Ltd. の最新の財務報告によると、現在の収益 (TTM) は $6.13B です。2023 年には $2.46B の収益があり、これは 2022 年の $1.42B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
BeiGene, Ltd. の収益履歴（2013 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $6.13B | 60.85% |
| 2024 | $3.81B | 54.96% |
| 2023 | $2.46B | 73.65% |
| 2022 | $1.42B | 20.37% |
| 2021 | $1.18B | 280.83% |
| 2020 | $308.87M | -27.87% |
| 2019 | $428.21M | 116.03% |
| 2018 | $198.22M | -16.85% |
| 2017 | $238.39M | 22,179.16% |
| 2016 | $1.07M | -87.86% |
| 2015 | $8.82M | -32.37% |
| 2014 | $13.04M | 16.93% |
| 2013 | $11.15M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 105.98% |
US
|
|
| $2.23B | -63.65% |
US
|
|
| $15.74B | 156.88% |
AU
|
|
| $6.02B | -1.76% |
NL
|
|
| - | - |
CH
|
